TherapeuticsMD, Inc DEFA14A, filed Apr 14, 2021

TherapeuticsMD, Inc. (TXMD)

DEFA14A 2021-04-14

Added on October 26, 2026


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐		Definitive Proxy Statement

☒		Definitive Additional Materials

☐		Soliciting Material Pursuant to §240.14a-12


☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	1)	Title of each class of securities to which transaction applies:
	2)	Aggregate number of securities to which transaction applies:
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:
	5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount previously paid:
	2)	Form, Schedule or Registration Statement No.:
	3)	Filing party:
	4)	Date Filed:




				Your Vote Counts!
				THERAPEUTICSMD, INC. 2021 Annual Meeting Vote by May 26, 2021 11:59 PM ET


THERAPEUTICSMD, INC. 951 YAMATO ROAD, SUITE 220 BOCA RATON, FL 33431







D45483-P55549


Voting Items			Board Recommends

1.	To elect directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified.

	Nominees:

	01) Tommy G. Thompson	06) Karen L. Ling

	02) Robert G. Finizio	07) Jules A. Musing	For

	03) Paul M. Bisaro	08) Gail K. Naughton, Ph.D.

	04) J. Martin Carroll	09) Angus C. Russell

	05) Cooper C. Collins

2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2020.		For

3.	To approve a stock option exchange program for those employees of the company who are not named executive officers.		For

4.	To approve an amendment to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan to increase the number of authorized shares thereunder.		For

5.	To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of the company for the fiscal year ending December 31, 2021.		For

6.	To transact such other business as may properly come before the meeting or any adjournment thereof.